Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients

Cathia Soulié*, Isabelle Malet, Sidonie Lambert-Niclot, Roland Tubiana, Monique Thévenin, Anne Simon, Robert Murphy, Christine Katlama, Vincent Calvez, Anne Geneviève Marcelin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Resistance to CCR5 antagonists can be driven by mutations in gp120. Sequences from 323 anti-CCR5 naive patients were analyzed for the presence of previously described in-vivo or in-vitro resistance mutations to CCR5 antagonists located in the V3 loop of gp120. The V3 loop region was rather polymorphic, and 7.3% of patients showed viruses with combinations of mutations in V3 loop previously described to be involved in maraviroc resistance, a licensed CCR5 antagonist.

Original languageEnglish (US)
Pages (from-to)2212-2214
Number of pages3
JournalAIDS
Volume22
Issue number16
DOIs
StatePublished - Nov 7 2008

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients'. Together they form a unique fingerprint.

Cite this